{"id":58788,"date":"2026-03-04T23:11:41","date_gmt":"2026-03-04T15:11:41","guid":{"rendered":"https:\/\/flcube.com\/?p=58788"},"modified":"2026-03-04T23:11:43","modified_gmt":"2026-03-04T15:11:43","slug":"edding-genor-expands-angptl3-sirna-rights-to-global-restructures-napeptide-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58788","title":{"rendered":"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership"},"content":{"rendered":"\n<p><strong>Edding Genor Group Holdings Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/6998:HKG\">HKG:\u202f6998<\/a>)<\/strong> announced a <strong>supplemental agreement<\/strong> and <strong>termination agreement<\/strong> with <strong>Napeptide (Qingdao) Biopharmaceutical Co., Ltd.<\/strong>, restructuring their <strong>siRNA collaboration<\/strong> originally established in <strong>September\u202f2023<\/strong> and <strong>May\u202f2024<\/strong>. The revised terms <strong>expand Edding Genor&#8217;s ANGPTL3 asset to global rights<\/strong> while <strong>terminating development of two other preclinical siRNA programs<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-restructuring-overview\">Restructuring Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Original Agreement<\/th><th>Date<\/th><th>Scope<\/th><\/tr><\/thead><tbody><tr><td><strong>Initial Licensing<\/strong><\/td><td>Sept\u202f2023<\/td><td>Exclusive rights to 2 preclinical siRNA assets<\/td><\/tr><tr><td><strong>Additional In\u2011License<\/strong><\/td><td>May\u202f2024<\/td><td>Third siRNA asset added<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-revised-terms-march-2026\">Revised Terms (March\u202f2026)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Adjustment<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>\u2460 ANGPTL3 Expansion<\/strong><\/td><td>Territorial scope expanded to <strong>global rights<\/strong><\/td><\/tr><tr><td><strong>Patent Rights<\/strong><\/td><td>Edding Genor obtains <strong>global patent rights<\/strong> to ANGPTL3 molecule<\/td><\/tr><tr><td><strong>Platform Co\u2011Ownership<\/strong><\/td><td><strong>GalNAc delivery technology<\/strong> co\u2011owned with Need Pharma<\/td><\/tr><tr><td><strong>\u2461 Termination<\/strong><\/td><td>Collaboration on <strong>2 other preclinical siRNA assets ended<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ANGPTL3 Focus:<\/strong> The <strong>global rights expansion<\/strong> signals <strong>Edding Genor&#8217;s strategic prioritization<\/strong> of the <strong>ANGPTL3 siRNA<\/strong>\u2014a <strong>validated cardiovascular target<\/strong> (see: vupanorsen, pelacarsen) with <strong>blockbuster potential<\/strong> in <strong>dyslipidemia and cardiovascular risk reduction<\/strong>.<\/li>\n\n\n\n<li><strong>GalNAc Platform Control:<\/strong> <strong>Co\u2011ownership of GalNAc (N\u2011acetylgalactosamine) delivery technology<\/strong>\u2014the <strong>industry standard for liver\u2011targeted siRNA<\/strong>\u2014provides <strong>long\u2011term competitive moat<\/strong> and <strong>platform expansion capabilities<\/strong> for additional liver\u2011expressed targets.<\/li>\n\n\n\n<li><strong>Portfolio Rationalization:<\/strong> <strong>Termination of two preclinical assets<\/strong> reflects <strong>disciplined capital allocation<\/strong>, focusing resources on the <strong>highest\u2011potential program<\/strong> rather than spreading investment across multiple early\u2011stage candidates.<\/li>\n\n\n\n<li><strong>Global Ambition:<\/strong> <strong>Worldwide patent rights<\/strong> position Edding Genor for <strong>US\/EU clinical development<\/strong> and <strong>multinational partnership<\/strong>, elevating the company from <strong>China\u2011focused<\/strong> to <strong>global biotech contender<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-angptl3-market-context\">ANGPTL3 Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>ANGPTL3 Biology<\/strong><\/td><td>Regulates triglyceride and LDL metabolism; loss\u2011of\u2011function mutations associated with cardiovascular protection<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Pfizer&#8217;s vupanorsen (siRNA) discontinued; Arrowhead&#8217;s pelacarsen (ASO) in Phase III; Ionis\/AKCEA developing ANGPTL3\u2011targeting therapies<\/td><\/tr><tr><td><strong>siRNA Advantage<\/strong><\/td><td>GalNAc\u2011conjugated siRNA enables <strong>quarterly dosing<\/strong> with <strong>deep, durable lipid lowering<\/strong>\u2014superior to monthly antibody alternatives<\/td><\/tr><tr><td><strong>Edding Genor Positioning<\/strong><\/td><td>Global rights + GalNAc co\u2011ownership creates <strong>integrated development capability<\/strong>; potential for <strong>first\u2011in\u2011class or best\u2011in\u2011class ANGPTL3 siRNA<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding ANGPTL3 IND filing timelines, global clinical development strategy, and GalNAc platform monetization potential. Actual results may differ due to risks including competitive ANGPTL3 program advancement, siRNA manufacturing scale\u2011up, and partnership negotiation outcomes for ex\u2011China commercialization.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030302337_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030302337_c.\"><\/object><a id=\"wp-block-file--media-55e52682-fe93-44d7-8ac5-ad13c0bbbdac\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030302337_c.pdf\">2026030302337_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030302337_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-55e52682-fe93-44d7-8ac5-ad13c0bbbdac\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Edding Genor Group Holdings Limited (HKG:\u202f6998) announced a supplemental agreement and termination agreement with Napeptide&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[957,953,4636,64],"class_list":["post-58788","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-edding-genor","tag-hkg-6998","tag-napeptide-biopharmaceutical","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Edding Genor Group Holdings Limited (HKG:\u202f6998) announced a supplemental agreement and termination agreement with Napeptide (Qingdao) Biopharmaceutical Co., Ltd., restructuring their siRNA collaboration originally established in September\u202f2023 and May\u202f2024. The revised terms expand Edding Genor&#039;s ANGPTL3 asset to global rights while terminating development of two other preclinical siRNA programs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58788\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership\" \/>\n<meta property=\"og:description\" content=\"Edding Genor Group Holdings Limited (HKG:\u202f6998) announced a supplemental agreement and termination agreement with Napeptide (Qingdao) Biopharmaceutical Co., Ltd., restructuring their siRNA collaboration originally established in September\u202f2023 and May\u202f2024. The revised terms expand Edding Genor&#039;s ANGPTL3 asset to global rights while terminating development of two other preclinical siRNA programs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58788\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T15:11:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T15:11:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58788#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58788\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership\",\"datePublished\":\"2026-03-04T15:11:41+00:00\",\"dateModified\":\"2026-03-04T15:11:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58788\"},\"wordCount\":380,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Edding Genor\",\"HKG: 6998\",\"Napeptide Biopharmaceutical\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58788#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58788\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58788\",\"name\":\"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-04T15:11:41+00:00\",\"dateModified\":\"2026-03-04T15:11:43+00:00\",\"description\":\"Edding Genor Group Holdings Limited (HKG:\u202f6998) announced a supplemental agreement and termination agreement with Napeptide (Qingdao) Biopharmaceutical Co., Ltd., restructuring their siRNA collaboration originally established in September\u202f2023 and May\u202f2024. The revised terms expand Edding Genor's ANGPTL3 asset to global rights while terminating development of two other preclinical siRNA programs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58788#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58788\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58788#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"Edding Genor Group Holdings Limited (HKG:\u202f6998) announced a supplemental agreement and termination agreement with Napeptide (Qingdao) Biopharmaceutical Co., Ltd., restructuring their siRNA collaboration originally established in September\u202f2023 and May\u202f2024. The revised terms expand Edding Genor's ANGPTL3 asset to global rights while terminating development of two other preclinical siRNA programs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58788","og_locale":"en_US","og_type":"article","og_title":"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership","og_description":"Edding Genor Group Holdings Limited (HKG:\u202f6998) announced a supplemental agreement and termination agreement with Napeptide (Qingdao) Biopharmaceutical Co., Ltd., restructuring their siRNA collaboration originally established in September\u202f2023 and May\u202f2024. The revised terms expand Edding Genor's ANGPTL3 asset to global rights while terminating development of two other preclinical siRNA programs.","og_url":"https:\/\/flcube.com\/?p=58788","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-04T15:11:41+00:00","article_modified_time":"2026-03-04T15:11:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58788#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58788"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership","datePublished":"2026-03-04T15:11:41+00:00","dateModified":"2026-03-04T15:11:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58788"},"wordCount":380,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Edding Genor","HKG: 6998","Napeptide Biopharmaceutical","RNAi \/ ASO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58788#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58788","url":"https:\/\/flcube.com\/?p=58788","name":"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-04T15:11:41+00:00","dateModified":"2026-03-04T15:11:43+00:00","description":"Edding Genor Group Holdings Limited (HKG:\u202f6998) announced a supplemental agreement and termination agreement with Napeptide (Qingdao) Biopharmaceutical Co., Ltd., restructuring their siRNA collaboration originally established in September\u202f2023 and May\u202f2024. The revised terms expand Edding Genor's ANGPTL3 asset to global rights while terminating development of two other preclinical siRNA programs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58788#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58788"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58788#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Edding Genor Expands ANGPTL3 siRNA Rights to Global \u2013 Restructures Napeptide Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58788"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58788\/revisions"}],"predecessor-version":[{"id":58790,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58788\/revisions\/58790"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58788"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}